ATE411036T1 - Verwendung von aplidine in der behandlung von pankreaskrebs - Google Patents

Verwendung von aplidine in der behandlung von pankreaskrebs

Info

Publication number
ATE411036T1
ATE411036T1 AT02770106T AT02770106T ATE411036T1 AT E411036 T1 ATE411036 T1 AT E411036T1 AT 02770106 T AT02770106 T AT 02770106T AT 02770106 T AT02770106 T AT 02770106T AT E411036 T1 ATE411036 T1 AT E411036T1
Authority
AT
Austria
Prior art keywords
aplidine
treatment
pancreas cancer
cancer
pancreas
Prior art date
Application number
AT02770106T
Other languages
English (en)
Inventor
R Mangues
R Henriquez
J Jimeno
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208624A external-priority patent/GB0208624D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE411036T1 publication Critical patent/ATE411036T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02770106T 2001-10-19 2002-10-21 Verwendung von aplidine in der behandlung von pankreaskrebs ATE411036T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34841201P 2001-10-19 2001-10-19
GB0208624A GB0208624D0 (en) 2002-04-15 2002-04-15 Use of aplidine for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
ATE411036T1 true ATE411036T1 (de) 2008-10-15

Family

ID=26247033

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770106T ATE411036T1 (de) 2001-10-19 2002-10-21 Verwendung von aplidine in der behandlung von pankreaskrebs

Country Status (9)

Country Link
US (2) US20050004012A1 (de)
EP (1) EP1435991B1 (de)
AT (1) ATE411036T1 (de)
AU (1) AU2002336206B2 (de)
CA (1) CA2462642A1 (de)
DE (1) DE60229414D1 (de)
ES (1) ES2315404T3 (de)
PT (1) PT1435991E (de)
WO (1) WO2003033013A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
EP1229922B1 (de) * 1999-11-15 2007-06-06 Pharma Mar, S.A. Behandlung von krebserkrankungen durch aplidin
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
KR20030038812A (ko) 2000-10-12 2003-05-16 파르마 마르, 에스.에이. 암 치료 방법
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
NZ541611A (en) 2003-03-12 2008-04-30 Dana Farber Cancer Inst Inc Aplidine for multiple myeloma treatment
MX2008010999A (es) * 2006-02-28 2008-09-08 Pharma Mar Sa Tratamientos anti-tumor mejorados.
WO2008080956A1 (en) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
EP2205263A1 (de) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Verbesserte antitumorbehandlungen
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
TWI807411B (zh) 2017-04-27 2023-07-01 西班牙商瑪製藥股份有限公司 抗腫瘤化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342744A (en) * 1979-07-19 1982-08-03 Lever Brothers Company Hair treatment products
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
FR2698543B1 (fr) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
AU681231B2 (en) * 1993-12-29 1997-08-21 Intarcia Therapeutics, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
AU740598B2 (en) * 1997-05-07 2001-11-08 William J. Crumb Aplidine as an L-type calcium channel enhancer
WO2000006134A2 (en) * 1998-07-30 2000-02-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP1229922B1 (de) * 1999-11-15 2007-06-06 Pharma Mar, S.A. Behandlung von krebserkrankungen durch aplidin
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
CA2423462A1 (en) * 2000-10-05 2002-04-11 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CA2462642A1 (en) 2003-04-24
DE60229414D1 (de) 2008-11-27
US20050004012A1 (en) 2005-01-06
US20100041594A1 (en) 2010-02-18
AU2002336206B2 (en) 2007-11-29
EP1435991A1 (de) 2004-07-14
EP1435991B1 (de) 2008-10-15
WO2003033013A1 (en) 2003-04-24
ES2315404T3 (es) 2009-04-01
PT1435991E (pt) 2009-01-16

Similar Documents

Publication Publication Date Title
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
DK0882021T3 (da) Nye phenanthridiner
DE60031248D1 (de) Elektroaktive pore
ID29070A (id) Fenilfenantridina dengan aktifitas pencegah pde-iv
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
TR199902751T2 (xx) Proteaz inhibit�rleri.
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
DK0998460T3 (da) Hidtil ukendte tetrazolderivater
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE411036T1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
ATE363531T1 (de) Claudin polypeptide
DE60019894D1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
DE59909760D1 (de) Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
DE60025327D1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
DK1214061T3 (da) Anvendelse af docetaxel til behandling af hepatocellulært carcinom
ATE295352T1 (de) Phenanthridine-n-oxide mit pde-iv hemmender wirkung
SE0301654D0 (sv) Novel compounds
PT1244643E (pt) Inibidores da triptase
ATE343390T1 (de) Kalzilytische verbindungen
TR200302193T4 (tr) Kombinasyon kemoterapisi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties